STOCK TITAN

T2 Biosystems Inc - TTOO STOCK NEWS

Welcome to our dedicated news page for T2 Biosystems (Ticker: TTOO), a resource for investors and traders seeking the latest updates and insights on T2 Biosystems.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect T2 Biosystems's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of T2 Biosystems's position in the market.

Rhea-AI Summary
T2 Biosystems highlights new studies supporting the T2Bacteria Panel, T2Candida Panel, and T2Resistance Panel at IDWeek conference. Data demonstrates speed, accuracy, and clinical benefits of T2Dx Instrument and sepsis panels.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.05%
Tags
clinical trial
-
Rhea-AI Summary
T2 Biosystems announces successful amendment and extension to its Term Loan Agreement with CRG Servicing LLC
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.4%
Tags
none
-
Rhea-AI Summary
T2 Biosystems announces preliminary Q3 financial results, including a decrease in total revenue of 60% compared to the prior year period. The company received FDA clearance for the T2Biothreat Panel and strengthened its balance sheet by converting debt into equity.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4612.64%
Tags
earnings
Rhea-AI Summary
T2 Biosystems submits 510(k) premarket notification to FDA to expand pathogen detection capabilities
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4612.64%
Tags
none
-
Rhea-AI Summary
T2 Biosystems announces reverse stock split
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-43.87%
Tags
none
-
Rhea-AI Summary
T2 Biosystems issues inducement awards to new employees
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary
T2 Biosystems to report Q3 2023 financial results and business updates
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
35.57%
Tags
conferences earnings
-
Rhea-AI Summary
T2 Biosystems receives FDA clearance for T2Biothreat Panel, allowing immediate marketing and sales in the US market. Panel detects six biothreat pathogens with high sensitivity and specificity. Clinical evaluation shows positive percent agreement of 100% for most targets. Pathogens detected can result in high mortality rates. Rapid and accurate diagnostic testing expected to play a key role in targeted antimicrobial treatment and minimizing economic impact.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-26.14%
Tags
clinical trial
-
Rhea-AI Summary
T2 Biosystems issues inducement awards to new employees
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary
T2 Biosystems to participate in Gilmartin Group Emerging Growth Company Showcase
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.66%
Tags
conferences acquisition
T2 Biosystems Inc

Nasdaq:TTOO

TTOO Rankings

TTOO Stock Data

21.39M
4.03M
0.54%
8.46%
10.47%
Small Arms, Ordnance, and Ordnance Accessories Manufacturing
Manufacturing
Link
US
Lexington

About TTOO

t2 biosystems is developing innovative diagnostic products to improve patient health. with two fda-cleared products targeting sepsis – the cause of one out of two hospital deaths - and a range of additional products in development, t2 biosystems is an emerging leader in the field of in vitro diagnostics. our initial development efforts target sepsis, hemostasis, bacteria and lyme disease, which are areas of significant unmet medical need. the company is utilizing its proprietary t2 magnetic resonance platform, or t2mr®, to develop a broad set of applications aimed at lowering mortality rates, improving patient outcomes and reducing the cost of healthcare by helping medical professionals make targeted treatment decisions earlier. at t2 biosystems, we know that our passion to advance the medical diagnostic landscape relies on our ability to attract and retain the very best people in the world – and to encourage them to flourish. we invite you to apply for one of our open positions at www